Hormonal Regulation FDA Approved

Gonadorelin

Also known as: GnRH

Molecular Identifiers

Molecular Formula

C55H75N17O13

PubChem CID

638793

Overview

Gonadotropin-releasing hormone (GnRH). Stimulates LH and FSH release from the pituitary gland. Research on the HPG axis. Pulsatile administration may be beneficial.

FDA-approved as Factrel for diagnostic use of gonadotropic function and as Lutrepulse for therapeutic pulsatile administration in the treatment of hypogonadotropic hypogonadism and infertility.

Sequence (1 letter): QHWSYGLRPG
Extended notation: Gln-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly

Half-life

~2-4 minutes

Administration Route

Subcutaneous or intravenous

Category

Hormonal Regulation

Mechanism of Action

  • Stimulation of LH and FSH release from the anterior pituitary
  • Regulation of the hypothalamic-pituitary-gonadal (HPG) axis
  • Pulsatile administration mimics endogenous secretion

Dosage Protocol

Data compiled from the literature. This does not constitute medical advice.

Parameter Value
Dose 100-200 mcg per injection
Frequency 2-3 times per week
Timing Any time of day
Duration As per research protocol

Reported Side Effects

Adverse effects described in the literature. Severity and frequency vary between individuals.

  • Headache
  • Facial flushing
  • Nausea
  • Injection site pain
  • Hot flashes

Presentations & Preparation

Vials of Gonadorelin found in the research market:

2 mg5 mg10 mg

Reconstitution

  • Diluent: Bacteriostatic water
  • Volume: 2 ml per vial
  • Slowly inject the diluent against the vial wall
  • Gently swirl until fully dissolved
  • Never shake

Storage

  • Lyophilized: Refrigerated 2-8°C
  • Reconstituted: Refrigerated 2-8°C (up to 30 days)
  • Protect from direct light
  • Do not freeze after reconstitution
Reconstitution Calculator

Scientific Studies

Published studies on Gonadorelin.

Related Peptides